Summit Therapeutics SMMT Business Segments — Interest Expense, Nonoperating

Similar metrics at other companies

SREReportable Segment — Interest Expense, Nonoperating

$147M+8.9%

CTREReportable Segment — Interest Expense

$11.24M+68.6%

BBIOReportable Segment — Interest Expense, Nonoperating

$12.94M-28.6%

NFLXReportable Segment — Interest Expense, Nonoperating

$262.08M+42.3%

INSMReportable Segment — Interest Expense

$20.08M-6.9%

RBAReportable Segment — Interest Expense

$44M-11.8%

Questions, answered.

What is Summit Therapeutics's business segments — interest expense, nonoperating?

Summit Therapeutics (SMMT) reported business segments — interest expense, nonoperating of $0 in Q4 2025.

How has Summit Therapeutics's business segments — interest expense, nonoperating changed year-over-year?

Summit Therapeutics's business segments — interest expense, nonoperating decreased by 100.0% year-over-year, from $9K to $0.

What is the long-term trend for Summit Therapeutics's business segments — interest expense, nonoperating?

Over 3 years (2022 to 2025), Summit Therapeutics's business segments — interest expense, nonoperating has grown at a -100.0% compound annual growth rate (CAGR), from $4.4M to $0.

What does business segments — interest expense, nonoperating mean?

The interest costs paid on debt or financial liabilities.

How do you interpret business segments — interest expense, nonoperating?

Increasing interest expense suggests higher debt levels or rising interest rates, which can pressure cash flow and increase financial risk.

How does business segments — interest expense, nonoperating compare across companies?

Standard line item for any company carrying debt; used to calculate interest coverage ratios.